● Recruiting

A Study of TPD3310 in Patients With Advanced Malignant Tumors

Condition: Advanced Malignant Solid Tumors · Sponsor: TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.

PhasePhase 1

Planned participants112

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This study is a multicenter, open phase I clinical study of dose escalation,cohort expansion study to evaluate the safety,tolerability,pharmacokinetics,pharmacodynamics, and preliminary efficacy of TPD3310 in patients withadvanced malignant solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Ning Li, M.D. · 8610-87788713 · lining@cicams.ac.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Recruiting

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →